SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Claims against Seres Therapeutics, Inc. and Advises Investors
with Losses to Contact the Firm
Goldberg Law PC announces that it is investigating Seres Therapeutics, Inc. (“Seres” or the “Company”) (Nasdaq:
MCRB) concerning possible violations of federal securities laws.
If you purchased or otherwise acquired Seres shares and would like more information regarding the investigation, we advise you
to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars Suite 1100, Los
Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at
http://www.Goldberglawpc.com, or by email at info@goldberglawpc.com.
The investigation concerns events around the Company’s announcement on July 29, 2016 that its Phase 2 clinical study for
ECOSPOR™ did not meet its primary endpoint of reducing the relative risk of Clostridium difficle infection recurrence. When this
news was released, shares of Seres dropped in value sharply. Two days before the announcement, however, the Company’s President,
CEO and Chairman of the Board sold 20,000 shares of Seres at a much higher price.
If you have any questions concerning your legal rights, please immediately contact Goldberg Law PC at 800-977-7401, or visit our
website at http://www.Goldberglawpc.com, or email us at info@goldberglawpc.com.
Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights
litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Goldberg Law PC, Los Angeles
Michael Goldberg, Esq., 800-977-7401
Brian Schall, Esq., 800-977-7401
info@goldberglawpc.com
http://www.Goldberglawpc.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20160801005880/en/